Eight-Week Clinical Research on Dzeny AI Therapist Demonstrates Clinically Significant Improvements Across Multiple Validated Mental Health Measures ...
- Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results